Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Three-week hepatitis B vaccination provides protective immunity

B Marchou1, N Picot, P Chavanet

  • 1Service des Maladies Infectieuses et Tropicals, Hôpital Purpan, Toulouse, France.

Vaccine
|November 1, 1993
PubMed
Summary

A 3-week hepatitis B (HB) vaccination schedule using GenHevac B demonstrated early and lasting protective immunity in young adults. Schedule B, with doses on days 0, 10, and 21, showed higher seroprotection rates and antibody titers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>In vivo</i> efficacy of enmetazobactam combined with cefepime in a murine pneumonia model induced by OXA-48-producing <i>Klebsiella pneumoniae</i>.

Microbiology spectrum·2024
Same author

Development of a new <i>Acinetobacter baumannii</i> pneumonia rabbit model for the preclinical evaluation of future anti-infective strategies.

Microbiology spectrum·2024
Same author

Efficacy of ceftaroline and rifampin, alone or combined, in a rat model of methicillin-resistant <i>Staphylococcus epidermidis</i> osteomyelitis without implant.

Microbiology spectrum·2023
Same author

Antibiotic therapy in the emergency room: Optimal prescription is indeed the best.

Infectious diseases now·2023
Same author

Why Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model?

Antimicrobial agents and chemotherapy·2021
Same author

Is there a need to widely prescribe antibiotics in patients hospitalized with COVID-19?

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2021

Area of Science:

  • Immunology
  • Vaccinology
  • Public Health

Background:

  • Hepatitis B (HB) remains a significant global health concern.
  • Establishing protective immunity rapidly is crucial for disease prevention.
  • Standard HB vaccination schedules may not always provide immediate protection.

Purpose of the Study:

  • To evaluate the efficacy of a compressed 3-week hepatitis B vaccination regimen.
  • To compare two different accelerated schedules for HB vaccine administration.
  • To assess the speed and durability of protective immunity induced by accelerated HB vaccination.

Main Methods:

  • 89 healthy, unvaccinated young adults received three doses of 20 micrograms HBs antigen (GenHevac B).
  • Participants were randomized into Schedule A (doses on days 0, 0, 21) or Schedule B (doses on days 0, 10, 21).

Related Experiment Videos

  • Seroprotection rates and anti-HBs geometric mean titers were measured at various time points.

    • Main Results:

    • At day 21, seroprotection rates were 23% (Schedule A) and 40% (Schedule B).
    • By day 82, rates increased to 77% (A) and 91% (B), with significantly higher titers in Schedule B.
    • One year post-vaccination, Schedule B maintained 90% seroprotection.

    Conclusions:

    • A 3-week hepatitis B vaccination schedule with GenHevac B can achieve early protective immunity.
    • Schedule B (doses on days 0, 10, 21) demonstrated superior immunogenicity and faster seroprotection.
    • This accelerated regimen offers a viable option for rapid and sustained protection against Hepatitis B.